Ocular inflammation associated with antivascular endothelial growth factor treatment
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: To describe the diagnosis and management of intraocular inflammation following antivascular endothelial growth factor (VEGF) injections. RECENT FINDINGS: Inflammation following intravitreal anti-VEGF injections can cause a dramatic reduction in acuity. Differentiating factors from truly infectious endophthalmitis include a lack of pain, redness, or hypopyon, although none of these factors is diagnostic. A high suspicion of infectious endophthalmitis should trigger a prompt vitreous tap and injection of intravitreal antibiotics. Conversely, if noninfectious endophthalmitis is suspected, close observation with frequent topical steroids is warranted. SUMMARY: Most eyes with noninfectious endophthalmitis following anti-VEGF injection recover within 1 month to baseline acuity with topical corticosteroid treatment. Mechanisms hypothesized to explain postinjection inflammation include patient-specific, delivery-specific, and medication-specific factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In sterile uveitis/endophthalmitis the mean visual acuity usually drops at presentation but often recovers after 1 month [2, 11, 19].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [2]
In the citing paper
“This inflammation may range from a mild transient reaction to potentially vision-threatening outcome after intravitreal injection of anti-VEGF therapy [2].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [2]
In the citing paper
“It is important to note that recurrent post-injection inflammation was found to be uncommon in previous studies [2, 11, 14, 22].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [2]
In the citing paper
“Less commonly, corneal edema, conjunctival injection, ocular pain, photophobia, hypopyon, keratic precipitates, trabeculitis, retinal infiltrates and hemorrhages may occur [2, 11, 12, 14, 16–19].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [2]
In the citing paper
“The timing of acute onset sterile inflammation following intravitreal anti-VEGF agents is rapid, typically within the first 5 days of injection [2, 11, 14].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [2]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.011 · Cited by 822
Fung, A. E., Rosenfeld, P. J., & Reichel, E. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.099598 · Cited by 532
Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES) (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0660-z · Cited by 456
Heier, J. S. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.11.1532 · Cited by 304
Complications in patients after intravitreal injection of bevacizumab
Shima, C., Sakaguchi, H., Gomi, F., Kamei, M., Ikuno, Y., Oshima, Y., Sawa, M., Tsujikawa, M., Kusaka, S., & Tano, Y. (2008) · Acta Ophthalmologica · doi:10.1111/j.1600-0420.2007.01067.x · Cited by 200
An Outbreak of Streptococcus Endophthalmitis After Intravitreal Injection of Bevacizumab
Goldberg, R. A., Flynn, H. W., Isom, R. F., Miller, D., & Gonzalez, S. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.11.035 · Cited by 156
Wickremasinghe, S. S., Michalova, K., Gilhotra, J., Guymer, R. H., Harper, C. A., Wong, T. Y., & Qureshi, S. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.05.007 · Cited by 124
Research works printed but not linked: 3
- Sheyman, 2013, J Am Med Assoc Ophthalmol, 131, 864
- Magalhaes, 2007, J Pharm Pharm Sci, 10, 388
- 2012, Ophthalmology, 119, 1388, 10.1016/j.ophtha.2012.03.053 · DOI · Paper page
Cited by
Anderson, W. J., da Cruz, N. F. S., Lima, L. H., Emerson, G. G., Rodrigues, E. B., & Melo, G. B. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00307-7 · Cited by 155
Kiss, S., Dugel, P. U., Khanani, A. M., Broder, M. S., Chang, E. Y., Sun, G. H., & Turpcu, A. (2018) · Clinical ophthalmology · doi:10.2147/opth.s169143 · Cited by 74
Endophthalmitis After Intravitreal Injections
Schwartz, S. G., Flynn, H. W., & Scott, I. U. (2009) · Springer eBooks · doi:10.1007/978-981-10-5260-6_14 · Cited by 60
Sterile Intraocular Inflammation Associated With Faricimab
Cozzi, M., Ziegler, A., Fasler, K., Muth, D. R., Blaser, F., & Zweifel, S. A. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.3828 · Cited by 49
Acharya, N. R., Vitale, A. T., Sugar, E. A., Holbrook, J. T., Burke, A. E., Thorne, J. E., Altaweel, M. M., Kempen, J. H., & Jabs, D. A. (2023) · Ophthalmology · doi:10.1016/j.ophtha.2023.04.011 · Cited by 38
Metadata
- Authors
- Fine, H. F., Despotidis, G. D., & Prenner, J. L.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- Corresponding author
- Fine, Howard F.
- Venue
- Current Opinion in Ophthalmology
- Published
- 2015-05
- Volume
- 26
- Issue
- 3
- Pages
- 184-187
- ISSN
- 1040-8738 (ISSN-L)
- OpenAlex
- W2006361998
- Cited by
- 35
- References
- 23
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 6 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 4 · 2018: 1 · 2016: 4
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- ocular inflammation, anti-VEGF therapy, intravitreal injection complications, infectious endophthalmitis, vitreous tap, intravitreal antibiotics, topical corticosteroids, visual acuity loss
- MeSH terms
- Administration, Topical, Diagnosis, Differential, Glucocorticoids, Humans, Endophthalmitis, Ophthalmic Solutions, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ocular inflammation associated with antivascular endothelial growth factor treatment. https://app.cochat.ai/papers/10.1097/icu.0000000000000154
- The paper
- Fine, H. F., Despotidis, G. D., & Prenner, J. L. (2015). Ocular inflammation associated with antivascular endothelial growth factor treatment. Current Opinion in Ophthalmology. https://doi.org/10.1097/icu.0000000000000154
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.